SGX-Mainboard listed CDW Holding Limited’s subsidiary, A Biotech Co. (ABio), has captured significant international interest with its LNP-LANFA drug-delivery technology at the BIO International Convention 2026 in San Diego. The platform, developed in collaboration with Neoregen Biotech, was showcased as a promising alternative to polyethylene glycol (PEG), addressing concerns over PEG’s immunogenicity and hypersensitivity.
ABio engaged in 37 meetings with pharmaceutical companies, biotech firms, and research organisations, presenting pre-clinical data from murine studies. These studies demonstrated a 3.3-fold improvement in the spleen-to-liver distribution ratio, crucial for vaccines and immune therapies. The enhanced splenic distribution is particularly valuable for targeting immune cells effectively.
The convention highlighted strong industry interest in PEG alternatives, driven by the need for safer drug delivery systems. ABio’s LANFA platform, patented in Japan, improves water solubility of compounds whilst maintaining biocompatibility, making it an attractive option for next-generation drug delivery systems.
Tomonori Kato, Chairman and CEO of CDW Holding, expressed optimism about the ongoing discussions with potential partners, stating, “We were encouraged by the level of technical engagement and the interest expressed in evaluating alternatives to PEG for future drug delivery applications.”
ABio plans to continue discussions with the organisations it met, exploring potential licensing and development collaborations. Whilst no definitive agreements have been reached, the interest generated at BIO USA 2026 marks a significant step forward for CDW Holding’s biotech ventures.
